Azelaic Acid 15% - Ivermectin 1% - Metronidazole 1% Cream Cream (Nourivan™ Antiox)

Total Formula Quantity

100 grams

Ingredients	Quantity	
Azelaic Acid	15 grams	
Ivermectin USP	1 grams	
Metronidazole USP	1 grams	
Propylene Glycol USP	15 grams	14.48 milliliters
Alcohol USP 200 Proof (Ethyl Alcohol 100%)	5 grams	6.3 milliliters
Nourivan™ Antiox	63 grams	

Ingredient Disclaimer

The density of Propylene Glycol is 1.036 g/mL
The density of Alcohol USP 200 Proof (Ethyl Alcohol 100%) is 0.794 g/mL

Method/Instructions

1. Calculate amount of ingredients needed.
2. Accurately weigh and measure each ingredient.
3. Add all ingredients to an appropriate size FagronLab EMP jar then mix for 3 - 4 minutes at a medium mix speed.
4. Process through Three Roll/Ointment Mill as needed.
5. Mix compound again for 1 minute at a low mix speed, or by hand, and package in an appropriate dispensing device.

Formulation Notes

- For optimal results this formulation should be compounded using mechanical mixing devices that ensure thorough mixing and produce high shearing forces (electronic mortar & pestle combined with processing through an ointment mill).

Equipment

FagronLab EMP

Supplies/Dispensers

Topi-Click | Topi-Pump | ExactDose Adapter | Syringe | Tube | Varionozzle

PPE Notes

Refer to USP <795> current guidelines for specific minimum garbing requirements. Gloves must be worn for all compounding activities. Additional garb may be necessary depending on the type of compounding performed and per the facility's SOP.

Storage

Controlled Room Temperature 20 to 25 °C | Protect from light | Store in a tightly closed container

BUD

Dating per USP <795>

- Non-preserved aqueous = 14 days
- Preserved aqueous = 35 days
- Nonaqueous oral liquids = 90 days
- Other nonaqueous dosage forms = 180 days

AUX

This medication was specially compounded in our pharmacy for you at the direction of your prescriber.

References

The ESTIMATED BEYOND-USE DATE is a physical stability estimate based on information from published references, medical and scientific literature, observed organoleptic stability, formulator practical experience and current USP guidelines. Please refer to USP Chapter <795> for additional information regarding appropriate Beyond-Use determination.

Disclaimer

This example compounding formulation (“Example Formula”) is being provided by Fagron Academy upon the request of Customer and is being provided for informational purposes only. Fagron Academy, its owners, officers, agents, affiliates and employees make no representation or warranty whatsoever with respect to this Example Formula. Customer is responsible for and, by its receipt of the Example Formula, agrees it will take any and all steps necessary to independently verify any formulation, concentrations, and raw amounts of components provided in this Example Formula, including any formulation that is the same or similar to the Example Formula, that is used in Customer’s business to ensure the accuracy of all product components and component concentrations, as well as the compatibility and stability of all formulation components. In consideration of being provided the Example Formula, Customer understands and agrees that Fagron Academy, its owners, officers, agents, affiliates and employees shall not be responsible for any claims, actions, liabilities, losses, expenses, damages, judgment or costs arising directly or indirectly or related in any way to any actual or alleged injury to any person (including death) or any damage to any tangible property resulting or claimed to result wholly or in part from any formulation that is the same or similar to any Example Formula.

Date last modified
01/22/2026